The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.102%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,960.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

1 Oct 2020 11:01

RNS Number : 8056A
Hikma Pharmaceuticals Plc
01 October 2020
 

Hikma Pharmaceuticals PLC

 

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

 

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

LTIP: 87,700 ordinary shares of 10 pence

 

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

LTIP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

LTIP: 30,198 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

LTIP: 57,502 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

MIP: 1,519,989 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

MIP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

MIP: 380,293 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

MIP: 1,139,696 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

EIP: 1,102,558 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

EIP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

EIP: 590,134 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

EIP: 512,424 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

LEI: 549300BNS685UXH4JI75

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRUPGUUUUPUGUG
Date   Source Headline
13th Apr 202111:35 amRNSBlock listing Interim Review
13th Apr 20219:19 amRNSTotal Voting Rights
17th Mar 20212:29 pmRNSDirector/PDMR Shareholding
17th Mar 202111:08 amRNSAnnual Financial Report
15th Mar 202111:24 amRNSDirector/PDMR Shareholding
11th Mar 20211:36 pmRNSHikma and GSK agree to cease potential acquisition
2nd Mar 20214:44 pmRNSDirector/PDMR Shareholding
25th Feb 20211:02 pmRNSDirector/PDMR Shareholding
25th Feb 20211:02 pmRNSDirector/PDMR Shareholding
25th Feb 20211:01 pmRNSDirector/PDMR Shareholding
25th Feb 20211:00 pmRNSDirector/PDMR Shareholding
25th Feb 20217:00 amRNSFinal Results
8th Feb 20212:55 pmRNSNotice of Results
26th Jan 20218:01 amRNSPotential Acquisition
15th Jan 20213:59 pmRNSHikma provides update on generic Advair Diskus®
13th Jan 20219:21 amRNSDirector/PDMR Shareholding
13th Jan 20219:14 amRNSDirector/PDMR Shareholding
18th Dec 202010:10 amRNSHolding(s) in Company
17th Dec 20205:30 pmRNSHikma launches generic Advair Diskus®
14th Dec 202012:57 pmRNSHolding(s) in Company
10th Dec 20204:00 pmRNSDirector/PDMR Shareholding
10th Dec 20203:51 pmRNSDirector/PDMR Shareholding
2nd Dec 20203:00 pmRNSTotal Voting Rights
2nd Dec 20201:05 pmRNSHolding(s) in Company
9th Nov 202011:38 amRNSHolding(s) in Company
5th Nov 202011:30 amRNSDirectorate Change
5th Nov 20207:00 amRNSHikma launches Icosapent Ethyl Capsules
5th Nov 20207:00 amRNSTrading Statement
2nd Nov 20201:20 pmRNSTotal Voting Rights
22nd Oct 20201:16 pmRNSNotice to Bondholders
8th Oct 20208:38 amRNSBlocklisting Application
1st Oct 202011:01 amRNSBlock listing Interim Review
22nd Sep 20207:00 amRNSHikma updates on ANDA for generic Advair Diskus®
3rd Sep 20203:15 pmRNSHikma receives favourable court ruling
2nd Sep 20209:30 amRNSTotal Voting Rights
7th Aug 20207:00 amRNSHalf-year Report
3rd Aug 20202:25 pmRNSTotal Voting Rights
16th Jul 202012:06 pmRNSNotice of Results
7th Jul 202012:48 pmRNSPublication of Offering Circular
25th Jun 20204:12 pmRNSHolding(s) in Company
25th Jun 20201:00 pmRNSDirectorate Change
23rd Jun 20205:30 pmRNSHikma Pharmaceuticals
23rd Jun 202011:39 amRNSHolding(s) in Company
23rd Jun 20207:00 amRNSResult of placing in Hikma Pharmaceuticals PLC
23rd Jun 20207:00 amRNSTransaction in Own Shares
22nd Jun 20205:13 pmRNSTransaction in Own Shares
22nd Jun 20205:09 pmRNSProposed Placing in Hikma Pharmaceuticals PLC
22nd Jun 202011:24 amRNSDirector/PDMR Shareholding
22nd Jun 202011:22 amRNSDirector/PDMR Shareholding
22nd Jun 202011:20 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.